JP2022511735A5 - - Google Patents

Info

Publication number
JP2022511735A5
JP2022511735A5 JP2021528350A JP2021528350A JP2022511735A5 JP 2022511735 A5 JP2022511735 A5 JP 2022511735A5 JP 2021528350 A JP2021528350 A JP 2021528350A JP 2021528350 A JP2021528350 A JP 2021528350A JP 2022511735 A5 JP2022511735 A5 JP 2022511735A5
Authority
JP
Japan
Prior art keywords
cells
neg
negative
enriched
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021528350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511735A (ja
JP7541516B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062695 external-priority patent/WO2020107002A2/en
Publication of JP2022511735A publication Critical patent/JP2022511735A/ja
Publication of JP2022511735A5 publication Critical patent/JP2022511735A5/ja
Priority to JP2024135820A priority Critical patent/JP2024161503A/ja
Application granted granted Critical
Publication of JP7541516B2 publication Critical patent/JP7541516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528350A 2018-11-21 2019-11-21 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 Active JP7541516B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135820A JP2024161503A (ja) 2018-11-21 2024-08-16 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770686P 2018-11-21 2018-11-21
US62/770,686 2018-11-21
PCT/US2019/062695 WO2020107002A2 (en) 2018-11-21 2019-11-21 Methods for expansion of natural killer (nk) cell subset and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135820A Division JP2024161503A (ja) 2018-11-21 2024-08-16 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2022511735A JP2022511735A (ja) 2022-02-01
JP2022511735A5 true JP2022511735A5 (cg-RX-API-DMAC7.html) 2022-11-30
JP7541516B2 JP7541516B2 (ja) 2024-08-28

Family

ID=68841253

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021528350A Active JP7541516B2 (ja) 2018-11-21 2019-11-21 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法
JP2024135820A Pending JP2024161503A (ja) 2018-11-21 2024-08-16 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135820A Pending JP2024161503A (ja) 2018-11-21 2024-08-16 ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法

Country Status (6)

Country Link
US (2) US12410402B2 (cg-RX-API-DMAC7.html)
EP (1) EP3884041A2 (cg-RX-API-DMAC7.html)
JP (2) JP7541516B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210123289A (cg-RX-API-DMAC7.html)
CN (1) CN113891934A (cg-RX-API-DMAC7.html)
WO (1) WO2020107002A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법
US20240197783A1 (en) * 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
IL310226A (en) * 2021-07-18 2024-03-01 Gamida Cell Ltd Therapeutic nk cell populations
CN119643843B (zh) * 2022-03-15 2025-08-12 上海君赛生物科技有限公司 肿瘤特异性免疫细胞标志物及其用途
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
CA2300957A1 (en) 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus and viral vectors
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999043208A1 (en) 1998-02-27 1999-09-02 The General Hospital Corporation The helios gene
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6168991B1 (en) 1999-06-25 2001-01-02 Lucent Technologies Inc. DRAM capacitor including Cu plug and Ta barrier and method of forming
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
WO2001045737A2 (en) 1999-12-22 2001-06-28 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
CA2498297A1 (en) 2002-09-09 2004-03-18 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
ES2678094T3 (es) 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009041113A1 (ja) 2007-09-28 2009-04-02 Olympus Corporation Fc受容体遺伝子導入NK細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009139921A2 (en) 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
JP2012521215A (ja) 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Nk細胞の増殖
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US11471486B2 (en) * 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
US20170137784A1 (en) * 2015-03-23 2017-05-18 Cellex Corporation NK Cell Culture Container And NK Cell Culture Method
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JP7033453B2 (ja) 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
EP3828266B1 (en) 2015-07-29 2022-11-23 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3349770A1 (en) 2015-09-14 2018-07-25 Regents of the University of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用
CN112839666A (zh) 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods

Similar Documents

Publication Publication Date Title
JP7654702B2 (ja) キメラ抗原受容体及び他の受容体の発現に対するt細胞
CN113543799B (zh) 靶向dll3的嵌合抗原受体和结合剂
ES2993360T3 (en) Subsets of human natural killer cells with enhanced antibody-directed immune responses
US20240316102A1 (en) Engineered natural killer (nk) cells and related methods
JP2020058380A (ja) キメラ抗原受容体及びその製造方法
EP3263595A1 (en) Fusion protein for use in the treatment of hvg disease
JP2021522839A5 (cg-RX-API-DMAC7.html)
CN111566201A (zh) 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法
CN113766919B (zh) 制造抗bcma car t细胞
JP2024527559A5 (cg-RX-API-DMAC7.html)
JP2024161503A (ja) ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法
CN107106609A (zh) 刺激和扩展t细胞的组合物和方法
JP2022008805A (ja) 腫瘍標的療法のためのcxcr6形質導入t細胞
WO2021016091A1 (en) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
KR20230022868A (ko) 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
JP2024540347A (ja) 記憶nk細胞と抗癌性二重特異性分子とによる組み合わせ癌療法
Märkl et al. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
WO2023193660A1 (zh) 增强型嵌合抗原受体及其应用
KR20230084155A (ko) 면역치료 조성물
WO2017040374A1 (en) Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
WO2000070022A9 (en) Ex vivo expansion of mammalian hematopoietic stem cells
WO2023082640A1 (zh) 增强免疫细胞持久性的方法
Chantzoura et al. The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity
Kenderian et al. Generating and expanding autologous chimeric antigen receptor T cells from patients with acute myeloid leukemia
ES3036043T3 (en) Methods for enhancing tcr alpha beta+ cell depletion efficiency